This site is intended for health professionals only

Wednesday 19 June 2019
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Thu, 25 Apr 2019
This major breakthrough and world-first could hail a new era in the design and production of new antibiotics and anticancer agents
Tue, 23 Apr 2019
Scientists from the Cancer Research UK Manchester Institute at The University of Manchester showed that a small volume of blood can contain up-to-date genetic information about a patient's cancer to inform treatment choices
Mon, 15 Apr 2019
This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences, cross-entity working groups with diverse functional group participation and clinical trial innovations
Fri, 12 Apr 2019
Improving results for patients by realising the transformational potential of Real World Data
Fri, 12 Apr 2019
Research conducted at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University, UK aimed to understand the development of bacterial resistance to four different topical antibiotics commonly used in some OTC sore throat medicines
Wed, 10 Apr 2019
Modelling study shows that up to 43% of the world’s future hepatitis C infections could be prevented if transmission among people who inject drugs was reduced
Wed, 10 Apr 2019
First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza